| Branded Generics India | Pharmaceutical formulations in dermatology, respiratory, cardio, gynecology segments | Strong brand equity, extensive marketing reach, regulatory compliance | Primarily B2C through pharmacies and hospitals, and B2B to healthcare providers | Specialty generics like respiratory and dermatology products | 448449 | 38 | Direct sales through distribution and retail channels | Market-based pricing with focus on affordable healthcare | Growing chronic disease demand, product innovations, expanded distribution network | Ryaltris, Ashlyna, Momate, VWash |
| North America Generics | FDA-approved generic drugs including injectables, respiratory, CNS products | FDA-approved manufacturing facility in Monroe, regulatory expertise, patent challenge capabilities | B2B focus: hospitals, pharmacies, and wholesalers in US market | Complex generics and injectable formulations | 301717 | 25 | Sales and licensing income from out-licensing agreements | Regulated market pricing, tenders, and exclusivity periods | Regulatory approvals, pipeline of Paragraph IV filings, manufacturing scale-up | Multiple ANDA approved generics including nasal sprays and injectables |
| Europe Pharmaceuticals | Generic and specialty prescription medicines focused on respiratory and dermatology | Established partner network, branded portfolio, regulatory licenses | B2B and B2C: retailers, hospitals, healthcare distributors across EU | Innovative branded products and niche generics | 300629 | 25 | Sale of pharmaceuticals through licencing and direct marketing | Market-regulated pricing and licensing arrangements | Product launches, regulatory approvals, and partnership agreements | Winlevi, Ryaltris, respiratory generics |
| Emerging Markets | Generics and branded formulations in dermatology, respiratory, diabetes in Asia, Latin America, Africa | Localized marketing and regulatory understanding, distribution networks | Healthcare providers, pharmacies, hospitals in emerging markets | Dermatology and respiratory portfolio | 281380 | 24 | Direct sales and licensing in emerging economies | Competitive pricing with market adaptation | Expanding healthcare access, growing chronic disease prevalence | Momate, Tacroz, Dermikelp |
